Tulathromycin A

DB11474ExperimentalVet approvedSmall molecule

Tulathromycin is a macrolide antibiotic used to treat bovine respiratory disease in cattle and swine respiratory disease in pigs. It is marketed by Pfizer Inc. under the tradename Draxxin.

Mechanism: Pharmacologically active on Cytosolic phospholipase A2
Curator reviewed
Formula / weight: C₄₁H₇₉N₃O₁₂ · 806.092 g/mol (avg)
Also known as: Tulathromycin
Code names: CP-472,295

Resolves to

Compound

UNII897A3KN7APCAS217500-96-4

Clinical / RWD

RxNorm1309314

Structure

InChIKeyGUARTUJKFNAVIK-QPTWMBCESA-NSMILES

[H][C@@]1(C[C@@](C)(OC)[C@](O)(CNCCC)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C

Targets

P47712PLA2G4A

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

56Drug interactionsStructured to mechanism, not free text

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tulathromycin A, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account